TULSA-PRO
Commercial- Indications
- Prostate cancer, Benign prostatic hyperplasia
Company intelligence / Profile preview
Profound Medical’s flagship product TULSA-PRO has demonstrated durable efficacy and safety in treating localized prostate cancer and BPH with over five years of clinical outcomes published. The CAPTAIN trial showed the procedure delivers safer and faster recoveries than robotic surgery. The company’s Sonalleve platform addresses uterine fibroids and palliative pain from bone metastases with regulatory approvals in multiple regions
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Profound Medical.